[go: up one dir, main page]

WO2025030095A1 - Procédés de synthèse - Google Patents

Procédés de synthèse Download PDF

Info

Publication number
WO2025030095A1
WO2025030095A1 PCT/US2024/040720 US2024040720W WO2025030095A1 WO 2025030095 A1 WO2025030095 A1 WO 2025030095A1 US 2024040720 W US2024040720 W US 2024040720W WO 2025030095 A1 WO2025030095 A1 WO 2025030095A1
Authority
WO
WIPO (PCT)
Prior art keywords
present
compound
concentration
formula
glucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/040720
Other languages
English (en)
Inventor
Brenden Paul DERSTINE
John Lloyd Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of WO2025030095A1 publication Critical patent/WO2025030095A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/002—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by oxidation/reduction reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01184—Carbonyl reductase (NADPH) (1.1.1.184)

Definitions

  • This present disclosure relates to methods of synthesis of intermediate compounds in the synthesis of muscarinic acetylcholine receptor (mAChR) agonists; in particular, the present disclosure relates to enzymatic processes utilising a ketoreductase to perform a stereoselective reduction of a ketone to an alcohol.
  • mAChR muscarinic acetylcholine receptor
  • the instant application contains a Sequence Listing which has been submitted electronically as an XML file named “46696-0184WO1 _ST26_SL.xml.”
  • the XML file created on July 31 , 2024, is 3,828 bytes in size.
  • the material in the XML file is hereby incorporated by reference in its entirety.
  • Muscarinic acetylcholine receptors are members of the G protein-coupled receptor superfamily which mediate the actions of the neurotransmitter acetylcholine in both the central and peripheral nervous system. Five mAChR subtypes have been cloned, M1 to M5.
  • Muscarinic receptors in the central nervous system play a critical role in mediating higher cognitive processing.
  • Diseases associated with cognitive impairments such as Alzheimer's disease, are accompanied by loss of cholinergic neurons in the basal forebrain (Whitehouse et al., 1982 Science).
  • schizophrenia which is also characterised by cognitive impairments, mAChR density is reduced in the pre-frontal cortex, hippocampus and caudate putamen of schizophrenic subjects (Dean et al., 2002 Mol Psychiatry).
  • AD Alzheimer's disease
  • APP membrane bound amyloid precursor protein
  • mAChR agonists display an atypical antipsychoticlike profile in a range of pre-clinical paradigms.
  • Muscarinic receptors have also been implicated in the neurobiology of addiction. The reinforcing effects of cocaine and other addictive substances are mediated by the mesolimbic dopamine system where behavioural and neurochemical studies have shown that the cholinergic muscarinic receptor subtypes play important roles in regulation of dopaminergic neurotransmission.
  • Muscarinic receptors are also involved in the control of movement and potentially represent novel treatments for movement disorders such as Parkinson’s disease, ADHD, Huntingdon’s disease, Tourette’s syndrome and other syndromes associated with dopaminergic dysfunction as an underlying pathogenetic factor driving disease.
  • mAChR agonists xanomeline, sabcomeline, milameline and cevimeline have all progressed into various stages of clinical development for the treatment of Alzheimer’s disease and/or schizophrenia.
  • xanomeline and other related mAChR agonists have displayed an unacceptable safety margin with respect to cholinergic side effects, including nausea, gastrointestinal pain, diarrhoea, diaphoresis (excessive sweating), hypersalivation (excessive salivation), syncope and bradycardia.
  • Muscarinic receptors are involved in central and peripheral pain. Pain can be divided into three different types: acute, inflammatory, and neuropathic.
  • muscarinic receptors Activation of muscarinic receptors has been shown to be analgesic across a number of pain states through the activation of receptors in the spinal cord and higher pain centres in the brain.
  • Increasing endogenous levels of acetylcholine through acetylcholinesterase inhibitors direct activation of muscarinic receptors with agonists or allosteric modulators has been shown to have analgesic activity.
  • blockade of muscarinic receptors with antagonists or using knockout mice increases pain sensitivity.
  • Evidence for the role of the M1 receptor in pain is reviewed by D. F. Fiorino and M. Garcia-Guzman, 2012.
  • WO2015/118342 describes certain mAChR agonist compounds including the compounds having the following structures:
  • trans-alcohol compound of Formula (A) which is an intermediate for an improved synthetic route to mAChR agonist compounds which display high levels of selectivity for the M1 and/or M4 mAChR over the M2 and M3 receptor subtypes.
  • One aspect of the present disclosure is a process for preparing a trans-alcohol compound of Formula (A): wherein: the process comprises the step of reducing a compound of Formula (B): in the presence of a ketoreductase enzyme having SEQ ID NO: 1 to provide the compound of Formula (A).
  • the step of reducing a compound of Formula (B) is performed in the presence of NADPH as a cofactor.
  • the NADPH cofactor is provided by a cofactor regeneration system comprising NADP + , glucose dehydrogenase, and glucose.
  • the NADP + is present in a concentration of about 5 mM; the glucose dehydrogenase is present in a concentration of about 1 g/L; and the glucose is present in a concentration of about 178 mM.
  • the NADP + is present in a concentration of about 15 mM; the glucose dehydrogenase is present in a concentration of about 0.45 g/L; and the glucose is present in a concentration of about 247 mM.
  • the compound of Formula (B) is present in a concentration of about 88 mM. In one embodiment, the compound of Formula (B) is present in a concentration of about 198 mM.
  • the ketoreductase enzyme having SEQ ID NO: 1 is present in a concentration of about 1 g/L. In one embodiment, the ketoreductase enzyme is present in a concentration of about 2 g/L.
  • the step of reducing a compound of Formula (B) is performed in the presence of potassium phosphate buffer. In one embodiment, the step of reducing a compound of Formula (B) is performed in the presence of about 100 mM potassium phosphate buffer. In one embodiment, the step of reducing a compound of Formula (B) is performed in the presence of about 100 mM potassium phosphate buffer at about pH 7.0.
  • the step of reducing a compound of Formula (B) is performed in the presence of:
  • NADPH as a cofactor
  • the NADPH cofactor is provided by a cofactor regeneration system comprising NADP + , glucose dehydrogenase, and glucose
  • the NADP + is present in a concentration of about 5 mM; the glucose dehydrogenase is present in a concentration of about 1 g/L; the glucose is present in a concentration of about 178 mM; the compound of Formula (B) is present in a concentration of about 88 mM; and the ketoreductase enzyme having SEQ ID NO: 1 is present in a concentration of about 1 g/L.
  • the NADP + is present in a concentration of about 15 mM; the glucose dehydrogenase is present in a concentration of about 0.45 g/L; the glucose is present in a concentration of about 247 mM; the compound of Formula (B) is present in a concentration of about 198 mM; and the ketoreductase enzyme having SEQ ID NO: 1 is present in a concentration of about 1 g/L.
  • the step of reducing a compound of Formula (B) comprising heating at about 30 °C. In one embodiment, the step of reducing a compound of Formula (B) comprises stirring for about 20-24 h.
  • compositions comprising a compound of Formula (A): wherein the compound of Formula (A) is present in a diastereomeric excess of about 96%de or about 97%de.
  • the compound of Formula (A) is present in a diastereomeric excess of about 96%de.
  • the compound of Formula (A) is present in a diastereomeric excess of about 97%de.
  • the present application provides processes for preparing intermediate compounds useful in the preparation of mAChR agonist compounds (e.g., the mAChR agonist compounds described in WO2015/118342), and salts thereof.
  • trans-alcohol intermediate described herein has the structure of the following Formula (A):
  • a synthetic route to the mAChR agonist compounds utilising the trans-alcohol intermediate compound described herein avoids the need to separate stereoisomers by preparative HPLC and therefore has improved developability for large scale synthesis.
  • mAChR agonist compounds may be produced via a synthetic route comprising the steps outlined in the following scheme: wherein Q 1 is / and Q 2 is -H; or Q 1 and Q 2 , together with the carbon atom to which they are attached form a cyclic ketal, e.g., Accordingly, provided herein are processes for preparing a trans-alcohol compound of Formula (A): wherein: the process comprises the step of reducing a compound of Formula (B): in the presence of a ketoreductase enzyme having SEQ ID NO: 1 to provide the compound of Formula (A).
  • the step of reducing a compound of Formula (B) is performed in the presence of NADPH as a cofactor.
  • the NADPH cofactor is provided by a cofactor regeneration system comprising NADP + , glucose dehydrogenase, and glucose.
  • the NADP + is present in a concentration of from about 5 mM to about 15 mM. In one embodiment, the NADP + is present in a concentration of about 5 mM. In one embodiment, the NADP + is present in a concentration of about 15 mM.
  • the glucose dehydrogenase is present in a concentration of from about 1 g/L to about 0.45 g/L. In one embodiment, the glucose dehydrogenase is present in a concentration of about 1 g/L. In one embodiment, the glucose dehydrogenase is present in a concentration of about 0.45 g/L.
  • the glucose is present in a concentration of from about 178 mM to about 247 mM. In one embodiment, the glucose is present in a concentration of about 178 mM. In one embodiment, the glucose is present in a concentration of about 247 mM.
  • the NADP + is present in a concentration of about 5 mM; the glucose dehydrogenase is present in a concentration of about 1 g/L; and the glucose is present in a concentration of about 178 mM. In one embodiment: the NADP + is present in a concentration of about 15 mM; the glucose dehydrogenase is present in a concentration of about 0.45 g/L; and the glucose is present in a concentration of about 247 mM.
  • the compound of Formula (B) is present in a concentration of from about 88 mM to about 198 mM. In one embodiment, the compound of Formula (B) is present in a concentration of about 88 mM. In one embodiment, the compound of Formula (B) is present in a concentration of about 198 mM.
  • the ketoreductase enzyme having SEQ ID NO: 1 is present in a concentration of about 1 g/L.
  • the step of reducing a compound of Formula (B) is performed in the presence of potassium phosphate buffer. In one embodiment, the step of reducing a compound of Formula (B) is performed in the presence of about 100 mM potassium phosphate buffer. In one embodiment, the step of reducing a compound of Formula (B) is performed in the presence of about 100 mM potassium phosphate buffer about pH 7.0.
  • the step of reducing a compound of Formula (B) is performed in the presence of:
  • NADPH as a cofactor wherein the NADPH cofactor is provided by a cofactor regeneration system comprising NADP + , glucose dehydrogenase, and glucose; and
  • the NADP + is present in a concentration of about 5 mM; the glucose dehydrogenase is present in a concentration of about 1 g/L; the glucose is present in a concentration of about 178 mM; the compound of Formula (B) is present in a concentration of about 88 mM; and the ketoreductase enzyme having SEQ ID NO: 1 is present in a concentration of about 1 g/L.
  • the NADP + is present in a concentration of about 15 mM; the glucose dehydrogenase is present in a concentration of about 0.45 g/L; the glucose is present in a concentration of about 247 mM; the compound of Formula (B) is present in a concentration of about 198 mM; and the ketoreductase enzyme having SEQ ID NO: 1 is present in a concentration of about 1 g/L.
  • the step of reducing a compound of Formula (B) comprises heating at about 30 °C. In one embodiment, the step of reducing a compound of Formula (B) comprises stirring for about 20-24 h.
  • the compound of Formula (A) is an intermediate compound which is useful in the synthesis of the mAChR agonist compounds described in WO2015/118342.
  • the compound of Formula (A) has a diastereomeric excess of about 96%de.
  • the compound of Formula (A) has a diastereomeric excess of about 97%de.
  • a composition comprising a compound of Formula (A): wherein the compound of Formula (A) is present in a diastereomeric excess of about 96%de or about 97%de.
  • the compound of Formula (A) is present in a diastereomeric excess of about 96%de.
  • the compound of Formula (A) is present in a diastereomeric excess of about 97%de.
  • reacting is used as known in the art and generally refers to the bringing together of chemical reagents in such a manner so as to allow their interaction at the molecular level to achieve a chemical or physical transformation.
  • the compounds described herein comprise one or more areas of restricted rotation giving rise to cis-trans isomerism. Cis-trans isomers may also be described herein as diastereomers. Accordingly, the compounds (e.g., intermediate compounds), produced by the methods described herein may be produced in a manner wherein at least 55% (e.g., at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, or 98%) of the compound is present as a single stereoisomer of the cis-trans pair.
  • at least 55% e.g., at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, or 98%
  • 99% or more (e.g., substantially all) of the total amount of the compound is present as a single cis-trans isomer.
  • the compound is present as a frans-isomer (e.g., an intermediate compound).
  • the compounds described herein may contain one or more isotopic substitutions, and a reference to a particular element includes within its scope all isotopes of the element.
  • a reference to hydrogen includes within its scope 1 H, 2 H (D), and 3 H (T).
  • references to carbon and oxygen include within their scope respectively 12 C, 13 C and 14 C and 16 O and 18 O.
  • a reference to a particular functional group also includes within its scope isotopic variations, unless the context indicates otherwise.
  • a reference to an alkyl group such as an ethyl group also covers variations in which one or more of the hydrogen atoms in the group is in the form of a deuterium or tritium isotope, e.g., as in an ethyl group in which all five hydrogen atoms are in the deuterium isotopic form (a perdeuteroethyl group).
  • the isotopes may be radioactive or non-radioactive.
  • the compounds may contain no radioactive isotopes. Such compounds are preferred for therapeutic use. However, the compound may contain one or more radioisotopes. Compounds containing such radioisotopes may be useful in a diagnostic context. Solvates
  • solvates are solvates formed by the incorporation into the solid-state structure (e.g. crystal structure) of the compounds of the present disclosure of molecules of a non-toxic pharmaceutically acceptable solvent (referred to below as the solvating solvent).
  • a non-toxic pharmaceutically acceptable solvent referred to below as the solvating solvent.
  • solvents include water, alcohols (such as ethanol, isopropanol and butanol) and dimethylsulfoxide.
  • Solvates can be prepared by recrystalising the compounds of the present disclosure with a solvent or mixture of solvents containing the solvating solvent.
  • Whether or not a solvate has been formed in any given instance can be determined by subjecting crystals of the compound to analysis using well known and standard techniques such as thermogravimetric analysis (TGE), differential scanning calorimetry (DSC) and X-ray crystallography.
  • TGE thermogravimetric analysis
  • DSC differential scanning calorimetry
  • X-ray crystallography X-ray crystallography.
  • the solvates can be stoichiometric or non-stoichiometric solvates.
  • Particularly preferred solvates are hydrates, and examples of hydrates include hemihydrates, monohydrates and dihydrates.
  • the compounds described herein may be anhydrous. Therefore, also described herein is an intermediate compound described herein in an anhydrous form (e.g., anhydrous crystalline form).
  • Ketoreductases catalyze the reduction of aldehydes and ketones to the corresponding primary and secondary alcohols, respectively.
  • KREDs The reduction catalyzed by KREDs requires a reduced cofactor as electron donor.
  • Some KREDs use reduced nicotinamide adenine dinucleotide (NADH) as a cofactor, other KREDs use reduced nicotinamide adenine dinucleotide phosphate (NADPH) and some ketoreductases accept both, NADH and NADPH.
  • NADH nicotinamide adenine dinucleotide
  • NADPH reduced nicotinamide adenine dinucleotide phosphate
  • KREDs in vitro use of KREDs in reduction processes requires a cofactor regeneration system to regenerate NADPH from NADP + or NADH from NAD + .
  • cofactor regeneration systems are glucose dehydrogenase (GDH) which takes glucose as a feedstock, or formate dehydrogenase which takes formate as a feedstock. These cofactor regeneration systems may be used in conjunction with KREDs.
  • KREDs are ubiquitous enzymes found in all kingdoms of life.
  • Well-known, commercially available KREDs are derived from horse liver (HLADH), baker's yeast (YADH) and from bacteria, such as Thermoanaerobium brockii (TBADH) and Lactobacillus kefir (LKADH).
  • HLADH horse liver
  • YADH baker's yeast
  • TAADH Thermoanaerobium brockii
  • LKADH Lactobacillus kefir
  • KREDs For industrial applications it is desirable to employ KREDs with a high specific activity and stereoselectivity. Another important criterion in the industrial use of KREDs is a long process stability, which often correlates with a high stability at elevated temperatures and a high solvent stability. It may also be desirable to employ KREDs with a high stereospecificity.
  • Enzyme A described herein and used in the processes described herein is a ketoreductase enzyme (KRED) having an amino acid sequence of SEQ ID NO: 1 :
  • Enzyme A may be produced by methods known in the art. For instance, methods for expression of enzymes in cellular (e.g., microbial) expression systems are well known and routine to those skilled in the art.
  • Enzyme A may be provided by or generated from a host cell (e.g., a microbial cell, such as E. Coli) comprising a polynucleotide and/or expression vector that encodes Enzyme A.
  • the host cell can be TOP10 E. Coli.
  • Enzyme A may be produced using the method disclosed in the Examples.
  • the polynucleotide may be DNA or RNA.
  • the polynucleotide may be single-stranded or double-stranded.
  • the polynucleotide may be provided in isolated/purified form, or within a host cell.
  • Enzyme A may be encoded by a polynucleotide and/or expression vector comprising a nucleotide sequence according to SEQ ID NO: 2:
  • the polynucleotide may consist of SEQ ID NO: 2.
  • the polynucleotide may be operatively linked to one or more heterologous regulatory or control sequences that control gene expression to create a recombinant polynucleotide capable of expressing the polypeptide.
  • Expression constructs containing a heterologous polynucleotide encoding the engineered ketoreductase can be introduced into appropriate host cells to express the corresponding ketoreductase.
  • the polynucleotides encoding the ketoreductase enzymes may be codon optimized for optimal production from the host organism selected for expression. For example, preferred codons used in bacteria are used to express the gene in bacteria; preferred codons used in yeast are used for expression in yeast; and preferred codons used in mammals are used for expression in mammalian cells.
  • a polynucleotide encoding a disclosed enzyme may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the isolated polynucleotide prior to its insertion into an expression vector may be desirable or necessary depending on the expression vector.
  • the techniques for modifying polynucleotides and nucleic acid sequences utilizing recombinant DNA methods are well known in the art. Guidance is provided in Sambrook et al., 2001 , Molecular Cloning: A Laboratory Manual, 3rd Ed., Cold Spring Harbor Laboratory Press; and Current Protocols in Molecular Biology, Ausubel. F. ed., Greene Pub. Associates, 1998, updates to 2006.
  • control sequence may be an appropriate promoter sequence, which can be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.
  • suitable promoters for directing transcription of the nucleic acid constructs of the present disclosure include the promoters obtained from the E.
  • Streptomyces coelicolor agarase gene (dagA), Bacillus subtilis levansucrase gene (sacB), Bacillus licheniformis alpha-amylase gene (amyL), Bacillus stearothermophilus maltogenic amylase gene (amyM), Bacillus amyloliquefaciens alpha-amylase gene (amyQ), Bacillus licheniformis penicillinase gene (penP), Bacillus subtilis xylA and xylB genes, and prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978, Proc. Natl Acad. Sci.
  • the control sequence may also be a signal peptide coding region that codes for an amino acid sequence linked to the amino terminus of a polypeptide and directs the encoded polypeptide into the cell's secretory pathway.
  • the 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region that encodes the secreted polypeptide.
  • the 5' end of the coding sequence may contain a signal peptide coding region that is foreign to the coding sequence.
  • the foreign signal peptide coding region may be required where the coding sequence does not naturally contain a signal peptide coding region.
  • the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to enhance secretion of the polypeptide.
  • any signal peptide coding region which directs the expressed polypeptide into the secretory pathway of a host cell of choice may be used.
  • the vector may be a plasmid, phage, MAC, virus, etc.
  • the plasmid may be a pET28a plasmid (see Nature 2020; https://doi.org/10.1038/s42003-020-0939-8).
  • the polynucleotide and/or expression vector may be synthesised by convention DNA synthesis techniques.
  • the polynucleotides encoding the enzyme can be prepared by standard solid-phase methods, according to known synthetic methods. Fragments of up to about 100 bases can be individually synthesized, then joined (e.g., by enzymatic or chemical litigation methods, or polymerase mediated methods) to form any desired continuous sequence.
  • the disclosed polynucleotides can be prepared by chemical synthesis using, e.g., the classical phosphoramidite method described by Beaucage et al., 1981 , Tet Lett 22:1859-69, or the method described by Matthes et al., 1984, EMBO J. 3:801-05, e.g., as it is typically practiced in automated synthetic methods.
  • the phosphoramidite method oligonucleotides are synthesized, e.g., in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.
  • nucleic acid can be obtained from any of a variety of commercial sources, such as The Midland Certified Reagent Company, Midland, TX, The Great American Gene Company, Ramona, CA, ExpressGen Inc. Chicago, IL, Operon Technologies Inc., Alameda, CA, and many others. Protecting Groups
  • the term “reacting” is used as known in the art.
  • the reacting involves two reagents, wherein one or more equivalents of the second reagent are used with respect to the first reagent.
  • the reacting steps of the processes described herein can be conducted for a time and under conditions suitable for preparing the identified product.
  • Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature.
  • a given reaction can be carried out in one solvent or a mixture of more than one solvent.
  • suitable solvents for a particular reaction step can be selected.
  • Suitable solvents can include halogenated solvents such as carbon tetrachloride, bromodichloromethane, dibromochloromethane, bromoform, chloroform, bromochloromethane, dibromomethane, butyl chloride, dichloromethane, tetrachloroethylene, trichloroethylene, 1 ,1,1 -trichloroethane, 1,1,2-trichloroethane, 1,1- dichloroethane, 2-chloropropane, 1 ,2-dichloroethane, 1 ,2-dibromoethane, hexafluorobenzene, 1 ,2,4-trichlorobenzene, 1,2-dichlorobenzene, chlorobenzene, fluorobenzene, mixtures thereof and the like.
  • halogenated solvents such as carbon tetrachloride, bromodichloromethane, dibromochloromethane, brom
  • Suitable ether solvents include: dimethoxymethane, tetrahydrofuran, 1,3-dioxane, 1 ,4- dioxane, furan, diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, triethylene glycol dimethyl ether, anisole, t-butyl methyl ether, mixtures thereof and the like.
  • Suitable protic solvents can include, by way of example and without limitation, water, methanol, ethanol, 2-nitroethanol, 2-fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 1- propanol, 2-propanol, 2-methoxyethanol, 1-butanol, 2-butanol, i-butyl alcohol, t-butyl alcohol, 2-ethoxyethanol, diethylene glycol, 1-, 2-, or 3- pentanol, neo-pentyl alcohol, t-pentyl alcohol, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol, or glycerol.
  • Suitable aprotic solvents can include, by way of example and without limitation, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), 1,3- dimethyl-3,4,5,6-tetrahydro-2(1 H)-pyrimidinone (DMPLI), 1 ,3-dimethyl-2-imidazolidinone (DMI), N methylpyrrolidinone (NMP), formamide, N-methylacetamide, N-methylformamide, acetonitrile, dimethyl sulfoxide (DMSO), propionitrile, ethyl formate, methyl acetate, hexachloroacetone, acetone, ethyl methyl ketone, ethyl acetate, sulfolane, N,N- dimethylpropionamide, tetramethylurea, nitromethane, nitrobenzene, or hexamethylphosphoramide.
  • Suitable hydrocarbon solvents include benzene, cyclohexane, pentane, hexane, toluene, cycloheptane, methylcyclohexane, heptane, ethylbenzene, m-, o-, or p-xylene, octane, indane, nonane, or naphthalene.
  • Suitable aqueous buffer solvents include phosphate buffers, tris buffers, barbital buffers, BES (N, N-Bis-(2-hydroxyethyl)-2-aminoethanesulphonic acid) buffers, and MOPS (3-(N- morpholino) propane sulphonic acid) buffers.
  • reaction temperatures will depend on, for example, the melting and boiling points of the reagents and solvent, if present; the thermodynamics of the reaction (e.g., vigorously exothermic reactions may need to be carried out at reduced temperatures); the kinetics of the reaction (e.g., a high activation energy barrier may need elevated temperatures); and the temperature range over which any enzymatic component is active I the temperature at which any enzymatic component is denaturated.
  • ambient temperature and “room temperature” or “rt” as used herein, are understood in the art, and refer generally to a temperature, e.g., a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 °C to about 30 °C.
  • reactions of the processes described herein can be carried out in air or under an inert atmosphere.
  • reactions containing reagents or products that are substantially reactive with air can be carried out using air-sensitive synthetic techniques that are well known to the skilled artisan.
  • Mobile phase water and acetonitrile mixture (60/40 water/acetonitrile) with 0.1% phosphoric acid.
  • Cr ra ns /some/- corresponds to the %Area of the peak in an HPLC chromatograph generated using the Chiral RP-HPLC method, and having a retention time of 5.6 min; and C c /s/ S o m er corresponds to the %Area of the peak in the HPLC chromatograph generated using the Chiral RP-HPLC method, and having a retention time of 7.1 min.
  • a photometric assay was used to screen a range of KRED enzymes for their utility in the transformation of Formula (B) to Formula (A).
  • 288 diverse KRED enzymes were provided as dried enzyme formulation in 96 microtiter plates. The enzymes were solubilized in an appropriate buffer solution to generate a clear solution, necessary for photometric measurement and screening.
  • the photometric measurement recorded the decrease of the absorption at 340 nm, which corresponds with an enzyme consuming the NADPH cofactor for a reductive reaction.
  • the collected data was analyzed and enzymes selected, which either showed a negative slope (lowest numbers chosen first) over 10 min of reaction time or an overall absolute absorbance of lower than 0.7 and decreasing abruption over 10 min.
  • a low starting absorbance is an indication for a highly active enzyme, that consumes the cofactor faster, than the technician can transfer the MTP to the MTP-reader.
  • GDH glucose dehydrogenase, CDX-901 , Codexis Inc.
  • Potassium phosphate buffer 100 mM pH 7.0
  • Enzyme A significantly out-performed the next best enzymes (Enzymes B-F) for conversion of starting material, while maintaining the highest level of stereoselectivity (diastereomeric excess) observed for the trans-alcohol (Formula (A)).
  • Synthetic DNA having SEQ ID NO: 2 and encoding Enzyme A was synthesised with codon optimisation for E. coli expression.
  • the synthetic DNA (SEQ ID No: 2) and pET28a were digested with Nde ⁇ and Xho ⁇ restriction endonucleases, purified, and ligated together employing T4 DNA ligase.
  • the resultant recombinant molecule was subsequently transformed into E. coli strain TOP10 and the desired expression construct verified by Sanger DNA sequencing. After transforming sequence verified plasmid DNA into the E.
  • coli protein expression host BL21(DE3) a single colony was used to inoculate 10 mL of LBP growth medium (10 g/L plant peptone, 10 g/L NaCI and 5 g/L yeast extract, supplemented with 35 pg/mL kanamycin), with culturing performed at 37 °C for 16 h with shaking at 200 rpm.
  • LBP growth medium 10 g/L plant peptone, 10 g/L NaCI and 5 g/L yeast extract, supplemented with 35 pg/mL kanamycin
  • This starter culture was then used to inoculate 1 L of TB growth medium (12 g/L plant peptone, 12 g/L glycerol, 9.96 g/L sodium phosphate dibasic, 20.4 g/L sodium phosphate monobasic, supplemented with 35 pg/mL kanamycin) in a 2 L baffled glass Erlenmeyer flask, which was incubated at 28 °C for 16 h to effect expression of Enzyme A.
  • the culture was then transferred into 2 x 500 mL centrifuge pots (Nalgene®) and centrifuged at 6000 g / 4 °C in a SLA3000 rotor using a Sorvall RC-5C centrifuge.
  • the bacterial pellets were then resuspended within their pots with 5 x pellet weight of 50 mM sodium phosphate buffer, pH 7.5. Subsequent to thorough re-suspension, the bacterial suspension was transferred into a 100 mL glass beaker for cell disruption, that was achieved using an MSE Soniprep 150 sonicator, configured with a 9.5mm sonication probe at 0 °C, for a total of 8 min (4 x 2 min intervals at 16 microns, with 4 min incubation time between cycles).
  • the disrupted cell suspension was then transferred into a 50 mL (Nalgene®) centrifuge pot and centrifuged at 13000 x g in a FiberliteTM F13-1 X60cy rotor for 45 min. Following centrifugation, the supernatant (approx. 40 mL), was carefully transferred into a 100 mL plastic container and placed at -20 °C for 16 h.
  • the frozen Enzyme A solution was then subjected to lyophilisation by freeze drying (Edwards SuperModulo) over 2 days, maintaining a pressure below 1 mbar throughout. The dried enzyme cake was pulverised thoroughly by crushing with a steel spatula into a free-flowing homogenous powder and stored at -20 °C between use.
  • Example 4 Analytical scale preparation of tert-butyl trans-2-hydroxy-6-azaspirof3.41octane-
  • Enzyme A 1 mg was placed into a 2 mL reaction tube. Into the tube was added 0.5 mL of a reaction mix consisting of 5 mM nicotinamide adenine dinucleotide phosphate (NADP + ), 2 mM magnesium chloride hexahydrate, 178 mM glucose anhydrous, 1 g/L glucose dehydrogenase (CDX-901 , Codexis Inc.), 5% (v/v) dimethyl sulfoxide (DMSO) and 20 g/L tert-butyl 2-oxo-6-azaspiro[3.4]octane-6-carboxylate in 100 mM potassium phosphate buffer.
  • NADP + nicotinamide adenine dinucleotide phosphate
  • CDX-901 1 g/L glucose dehydrogenase
  • DMSO dimethyl sulfoxide
  • DMSO dimethyl sulfoxide
  • the reaction tube was shaken at 1000 rpm and 30°C for 24 h.
  • the reaction was analyzed using the chiral HPLC method showing a conversion in a range of 98.7% - 100% and a diastereomeric excess of 97%de for tert-butyl trans-2-hydroxy-6-azaspiro[3.4]octane-6- carboxylate.
  • Example 5 Lab-bench scale preparation of tert-butyl trans-2-hydroxy-6-azaspirof3.41octane- 6-carboxylate (20 g/L substrate)
  • tert-butyl 2-oxo-6- azaspiro[3.4]octane-6-carboxylate 20 g/L, 88 mM
  • dimethyl sulfoxide 5% v/v, DMSO
  • the reaction was analyzed using the chiral RP-HPLC method showing a conversion of 100% and a diastereomeric excess of 96%de for tert-butyl trans-2- hydroxy-6-azaspiro[3.4]octane-6-carboxylate.
  • Example 6 Lab-bench scale preparation of tert-butyl trans-2-hydroxy-6-azaspirof3.41octane- 6-carboxylate (45 g/L substrate)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente divulgation concerne des procédés de préparation d'un composé de formule (A) qui est utile en tant qu'intermédiaire dans la préparation de composés agonistes de mAChR ; et des compositions comprenant le composé de formule (A).
PCT/US2024/040720 2023-08-03 2024-08-02 Procédés de synthèse Pending WO2025030095A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363517371P 2023-08-03 2023-08-03
US63/517,371 2023-08-03

Publications (1)

Publication Number Publication Date
WO2025030095A1 true WO2025030095A1 (fr) 2025-02-06

Family

ID=92458128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/040720 Pending WO2025030095A1 (fr) 2023-08-03 2024-08-02 Procédés de synthèse

Country Status (1)

Country Link
WO (1) WO2025030095A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060444A1 (fr) * 2001-01-29 2002-08-08 UNIVERSITY OF TOLEDO, THE a University instrumentality of the State of Ohio Agonistes de recepteur muscarinique
WO2015118342A1 (fr) 2014-02-06 2015-08-13 Heptares Therapeutics Limited Composés aza bicycliques en tant qu'agonistes du récepteur muscarinique m1.
WO2017021728A1 (fr) * 2015-08-03 2017-02-09 Heptares Therapeutics Limted Agonistes muscariniques
WO2024028458A2 (fr) * 2022-08-04 2024-02-08 Heptares Therapeutics Limited Agonistes du récepteur muscarinique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060444A1 (fr) * 2001-01-29 2002-08-08 UNIVERSITY OF TOLEDO, THE a University instrumentality of the State of Ohio Agonistes de recepteur muscarinique
WO2015118342A1 (fr) 2014-02-06 2015-08-13 Heptares Therapeutics Limited Composés aza bicycliques en tant qu'agonistes du récepteur muscarinique m1.
WO2017021728A1 (fr) * 2015-08-03 2017-02-09 Heptares Therapeutics Limted Agonistes muscariniques
WO2024028458A2 (fr) * 2022-08-04 2024-02-08 Heptares Therapeutics Limited Agonistes du récepteur muscarinique

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1998, GREENE PUB. ASSOCIATES
"Useful proteins from recombinant bacteria", SCIENTIFIC AMERICAN, vol. 1980, no. 242, pages 74 - 94
BEAUCAGE ET AL., TET LETT, vol. 22, 1981, pages 1859 - 69
BRIDGES ET AL., BIOORG MED CHEM LETT, 2008
BUDZIK ET AL., ACS MED CHEM LETT, 2010
DEAN ET AL., MOL PSYCHIATRY, 2002
DEBOER ET AL., PROC. NATL ACAD. SCI. USA, vol. 80, 1983, pages 21 - 25
JOHNSON C. R. ET AL: "Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders", BIOMEDICINES, vol. 10, no. 2, 7 February 2022 (2022-02-07), Basel, pages 398, XP093222286, ISSN: 2227-9059, DOI: 10.3390/biomedicines10020398 *
JOHNSON ET AL., BIOORG MED CHEM LETT, 2010
MATTHES ET AL., EMBO J., vol. 3, 1984, pages 801 - 05
NATURE, 2020
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
T. GREENEP. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY AND SONS
VILLA-KAMAROFF ET AL., PROC. NATL ACAD. SCI. USA, vol. 75, 1978, pages 3727 - 3731
WHITEHOUSE ET AL., SCIENCE, 1982

Similar Documents

Publication Publication Date Title
EP2900669B1 (fr) Dérivés du héxahydropyrrolo[3,4-c]pyrrole et composés similaires en tant qu'inhibiteurs de l'autotaxine (atx) et inhibiteurs de la production de l'acid lysophosphatidique (lpa) pour traiter des maladies rénales
JP7297738B2 (ja) 疾患の治療のための化合物、その塩、及び方法
US20250057861A1 (en) Halogenated psilocybin derivatives and methods of using
US7067526B1 (en) 28-epirapalogs
TW201625646A (zh) 新穎７員雙環化合物
KR102204805B1 (ko) 항체-리파마이신 접합체의 제조 방법
CN1662541A (zh) 呋喃基化合物
TW202330549A (zh) Lrrk2抑制劑
CN1037773C (zh) 含杂原子的三环化合物
KR20230022982A (ko) Cav1.2 활성제로서의 메틸 2-(플루오로메틸)-5-옥소-4-페닐-4,5,6,7-테트라하이드로-1h-시클로펜타[b]피리딘-3-카르복실레이트 및 메틸 2-(플루오로메틸)-5-옥소-4-페닐-1,4,5,7-테트라하이드로푸로[3,4-b]피리딘-3-카르복실레이트
CN112899246A (zh) 醛酮还原酶KmAKR突变体及其催化合成手性醇的应用
WO2025030095A1 (fr) Procédés de synthèse
EP4308576B1 (fr) Nouveaux dérivés de thiazolopyrimidinone
Butora Toward a practical synthesis of morphine. The first several generations of a radical cyclization approach
EP4508045B1 (fr) Formes de sel citrate d'un agoniste du récepteur muscarinique
HK1080469A1 (zh) 稠合杂环异恶唑啉衍生物和它们作为抗抑郁剂的用途
US10287247B2 (en) Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
CN112538468B (zh) 一种Perakine还原酶突变体及其应用
CN1059724A (zh) 新的萘并三环化合物
CN1675222A (zh) C－取代的三环异噁唑啉衍生物及其作为抗抑郁剂的用途
CN120987828A (zh) 一种奥格列龙中间体和制备奥格列龙关键中间体的方法
US20240034739A1 (en) Processes for making bicyclic ketone compounds
WO2023170115A1 (fr) Dérivés de pyrido[1,2-a]pyrimidin-4-one
JP2016127832A (ja) セレンテラジン類縁体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24758429

Country of ref document: EP

Kind code of ref document: A1